Ivuxolimab - Pfizer
Alternative Names: anti-OX40R-11D4; B110; OX 40; PF-04518600; PF-8600Latest Information Update: 05 Nov 2023
At a glance
- Originator Pfizer
- Developer Dana-Farber Cancer Institute; M. D. Anderson Cancer Center; National Cancer Institute (USA); Pfizer; University of Southern California
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action OX40 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Renal cell carcinoma; Solid tumours; Triple negative breast cancer
- Phase I/II Acute myeloid leukaemia; Squamous cell cancer
- Phase I Follicular lymphoma
Most Recent Events
- 10 Dec 2022 Phase-Ib development for Follicular lymphoma (Combination therapy, Second-line therapy or greater) is ongoing in USA (IV) (NCT03636503)
- 10 Dec 2022 Phase-Ib development for Follicular lymphoma (Combination therapy, First-line therapy) is ongoing in USA (IV) (NCT03636503)
- 10 Dec 2022 Efficacy and adverse events data from a phase Ib trial in Follicular lymphoma presented at the 64th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2022)